Pas de connexion internet — affichage de la version enregistrée de la page.

Molecular Partner…

CHCHF
← Vers le Screener

Molecular Partners AG (US:MLLCF) — Biotechnology: Biological Products (No Diagnostic Substances). Nombre de places boursières sur lesquelles les actions de la société sont cotées : 3. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.

À propos de l'entreprise

Site Web
molecularpartners.com
Secteur
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Siège Social
Schlieren-Zurich, Switzerland
PDG
Patrick Amstutz
Employés
134
Actions en Circulation
38.31 M
Flottant
20.71 M
Capitalisation Boursière
127.56 M CHF
Initiés
8.47%
Investisseurs Institutionnels
43.8%
Secteur d'Activité (SIC)
Biological Products, (No Diagnostic Substances)
Forme Juridique
MVII
ISIN
US60853G1067
LEI
875500AXMLDAZ4D21744
FCF
−52.0 M CHF
Dette
?
Résultats et FCF — pour les 12 mois à 31.12.2025 (dernier rapport de l'entreprise).
Description

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

publicité

Bourses et Tickers

BourseTickerDevisePrixType
SW SIX Swiss ExchangeMOLN principaleCHF3.33 -0.30%actions ordinaires
LSE London Stock Exchange0QXX IOBCHF3.39 +0.00%actions ordinaires
US USA StocksMLLCF OTCUSD4.01 +0.00%actions ordinaires

Cours sur 3 Mois

US:MLLCF n'a pas fait l'objet de transactions au cours des 3 derniers mois — le graphique affiche SW:MOLN
jour de hausse jour de baisseSurvolez / touchez un jour — cours d'ouverture, de clôture, plus haut et plus bas

Principaux Actionnaires

DétenteurParticipationActionsDate du Rapport
Old Mission Capital, LLC0.03%11 3472025-06-30
DFA INVESTMENT DIMENSION…0.01%3 9232026-07-31
DFA INVESTMENT DIMENSION…0.01%3 5032026-07-31
American Century ETF Tru…0%122026-08-31